Patent · US Active

Gene editing-based method of attenuating the beta-amyloid pathway

US11173216B2 · kind B2 · utility

1Cited by
0References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 18, 2019
Grant dateNov 16, 2021
Priority date—
Expiry dateAug 31, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are CRISPR/Cas9 constructs designed for the C-terminal truncation of human amyloid precursor protein (APP) as well as methods of making and using such a construct. A Cas9 nuclease/gRNA ribonucleoprotein directs cleavage of an APP gene to provide a C-terminal truncated APP having a length of 659, 670, 676, or 686 amino acids, relative to the human or mouse APP sequence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.